Track market-moving stories before they get noisy

The sale occurred on Aug. 21 and was valued at approximately $541,000. The disposition reduced the executive's direct equity holdings by 7%.

A month has gone by since the last earnings report for Chemed (CHE - Free Report) . Shares have added about 1.7% in that time frame, underperforming the S&P 500.

But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Chemed due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important drivers.

Chemed Tops Q2 Earnings & Revenue EstimatesChemed Corporation reported second-quarter 2026 adjusted earnings per share of $6.06, up 41.9% year over year. The figure surpassed the Zacks Consensus Estimate by 9.2%.

The company’s GAAP earnings per share were $5.13, up 43.7% from last year’s reported figure.

CHE’s Q2 RevenuesRevenues in the reported quarter totaled $673.3 million, up 8.8% from the year-ago quarter’s figure. The metric topped the Zacks Consensus Estimate by 1.9%.

Chemed’s Raises 2026 GuidanceFor 2026, the company now expects rVITAS revenue-growth guidance excluding Medicare Cap, to increase 8.25-9.25% (earlier 6.5-7.5%). The Zacks Consensus Estimate for total revenues is pegged at $2.67 billion, which indicates a 7.4% year-over-year improvement.

Adjusted EPS for the year is now expected to be in the band of $25.00-$25.75 (previously $24.00-$24.75). The Zacks Consensus Estimate for the metric is pegged at $25.00. 

How Have Estimates Been Moving Since Then?Analysts were quiet during the last two month period as none of them issued any earnings estimate revisions.

The consensus estimate has shifted 6.27% due to these changes.

VGM ScoresAt this time, Chemed has a nice Growth Score of B, though it is lagging a bit on the Momentum Score front with a C. Following the exact same course, the stock has a score of C on the value side, putting it in the middle 20% for this investment strategy.

Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook Chemed has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry PlayerChemed is part of the Zacks Medical - Outpatient and Home Healthcare industry. Over the past month, Quest Diagnostics (DGX - Free Report) , a stock from the same industry, has gained 4.2%. The company reported its results for the quarter ended June 2026 more than a month ago.

Quest Diagnostics reported revenues of $3.04 billion in the last reported quarter, representing a year-over-year change of +10.2%. EPS of $3.12 for the same period compares with $2.62 a year ago.

For the current quarter, Quest Diagnostics is expected to post earnings of $2.85 per share, indicating a change of +9.6% from the year-ago quarter. The Zacks Consensus Estimate has changed +1.1% over the last 30 days.

Quest Diagnostics has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of B.

Deutsche Bank AG acquired a new position in shares of Chemed Corporation (NYSE:CHE – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 16,747 shares of the company’s stock, valued at approximately $7,800,000. Deutsche Bank AG owned about 0.13% of Chemed at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Commonwealth Equity Services LLC boosted its holdings in shares of Chemed by 3.1% in the 4th quarter. Commonwealth Equity Services LLC now owns 734 shares of the company’s stock worth $314,000 after purchasing an additional 22 shares during the period. Cim LLC increased its position in shares of Chemed by 1.1% during the 3rd quarter. Cim LLC now owns 2,139 shares of the company’s stock valued at $958,000 after purchasing an additional 24 shares during the last quarter. Eukles Asset Management raised its holdings in Chemed by 0.4% during the 4th quarter. Eukles Asset Management now owns 6,056 shares of the company’s stock valued at $2,591,000 after buying an additional 25 shares during the period. MassMutual Private Wealth & Trust FSB raised its holdings in Chemed by 65.3% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 81 shares of the company’s stock valued at $38,000 after buying an additional 32 shares during the period. Finally, EverSource Wealth Advisors LLC raised its holdings in Chemed by 9.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 406 shares of the company’s stock valued at $153,000 after buying an additional 35 shares during the period. 95.85% of the stock is currently owned by hedge funds and other institutional investors.

Chemed Trading Up 0.1% Shares of NYSE CHE opened at $541.33 on Monday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.89 and a current ratio of 0.91. The business’s 50 day moving average price is $499.24 and its 200-day moving average price is $446.50. Chemed Corporation has a fifty-two week low of $365.20 and a fifty-two week high of $557.00. The company has a market cap of $7.08 billion, a price-to-earnings ratio of 27.19, a PEG ratio of 2.05 and a beta of 0.51.

Chemed (NYSE:CHE – Get Free Report) last posted its quarterly earnings data on Tuesday, July 28th. The company reported $6.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.60 by $0.46. Chemed had a return on equity of 31.77% and a net margin of 10.60%.The company had revenue of $673.25 million during the quarter, compared to analysts’ expectations of $665.04 million. During the same quarter in the previous year, the business earned $4.27 EPS. Chemed’s revenue was up 8.8% compared to the same quarter last year. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. On average, sell-side analysts expect that Chemed Corporation will post 23.18 earnings per share for the current year. Chemed Increases Dividend The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 3rd. Stockholders of record on Monday, August 17th will be given a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a dividend yield of 0.5%. This is a positive change from Chemed’s previous quarterly dividend of $0.60. The ex-dividend date is Monday, August 17th. Chemed’s dividend payout ratio is 14.06%.

Analyst Ratings Changes CHE has been the subject of several recent analyst reports. Bank of America reaffirmed a “neutral” rating on shares of Chemed in a research note on Wednesday, July 29th. Weiss Ratings raised shares of Chemed from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, July 17th. Royal Bank Of Canada raised their target price on shares of Chemed from $436.00 to $548.00 and gave the stock a “sector perform” rating in a report on Thursday, July 30th. Zacks Research upgraded shares of Chemed from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. Finally, Oppenheimer lifted their price target on shares of Chemed from $500.00 to $590.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $530.75.

View Our Latest Research Report on CHE

Insider Transactions at Chemed In other news, CEO Kevin J. Mcnamara sold 2,000 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $539.51, for a total transaction of $1,079,020.00. Following the completion of the sale, the chief executive officer directly owned 70,418 shares of the company’s stock, valued at approximately $37,991,215.18. The trade was a 2.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Andrea R. Lindell sold 1,347 shares of the company’s stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $447.33, for a total transaction of $602,553.51. Following the completion of the transaction, the director owned 4,578 shares in the company, valued at approximately $2,047,876.74. The trade was a 22.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 3,537 shares of company stock worth $1,782,654. 3.33% of the stock is currently owned by insiders.

Chemed Profile (Free Report)

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.

Featured Articles Five stocks we like better than Chemed VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corporation (NYSE:CHE – Free Report).

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.

Abacus FCF Advisors LLC acquired a new stake in shares of Chemed Corporation (NYSE:CHE – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 8,239 shares of the company’s stock, valued at approximately $3,837,000. Abacus FCF Advisors LLC owned approximately 0.06% of Chemed at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Chemed by 2,444,879.3% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 5,550,103 shares of the company’s stock worth $2,374,667,000 after buying an additional 5,549,876 shares during the last quarter. BlackRock Inc. purchased a new stake in Chemed in the second quarter valued at $691,290,000. Norges Bank purchased a new stake in Chemed in the fourth quarter valued at $76,067,000. AQR Capital Management LLC grew its position in Chemed by 89.2% during the 4th quarter. AQR Capital Management LLC now owns 325,579 shares of the company’s stock worth $139,302,000 after purchasing an additional 153,469 shares during the period. Finally, Victory Capital Management Inc. grew its position in Chemed by 1,260.2% during the 4th quarter. Victory Capital Management Inc. now owns 117,685 shares of the company’s stock worth $50,353,000 after purchasing an additional 109,033 shares during the period. 95.85% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth A number of equities research analysts have recently commented on the stock. Oppenheimer raised their price objective on shares of Chemed from $500.00 to $590.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. Weiss Ratings raised Chemed from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, July 17th. Zacks Research raised shares of Chemed from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Bank of America restated a “neutral” rating on shares of Chemed in a research report on Wednesday, July 29th. Finally, Wall Street Zen upgraded Chemed from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 1st. One equities research analyst has rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, Chemed has an average rating of “Hold” and a consensus target price of $530.75.

Read Our Latest Stock Analysis on CHE Insider Activity at Chemed In related news, Director Andrea R. Lindell sold 1,347 shares of Chemed stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $447.33, for a total value of $602,553.51. Following the completion of the transaction, the director owned 4,578 shares in the company, valued at approximately $2,047,876.74. The trade was a 22.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Patrick P. Grace sold 190 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $532.00, for a total transaction of $101,080.00. Following the sale, the director directly owned 3,533 shares in the company, valued at approximately $1,879,556. The trade was a 5.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 3,537 shares of company stock worth $1,782,654. Corporate insiders own 3.33% of the company’s stock.

Chemed Stock Performance Chemed stock opened at $535.86 on Thursday. The firm has a 50 day simple moving average of $494.52 and a 200-day simple moving average of $445.00. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.91 and a quick ratio of 0.89. The stock has a market cap of $7.00 billion, a price-to-earnings ratio of 26.91, a price-to-earnings-growth ratio of 2.00 and a beta of 0.51. Chemed Corporation has a 1-year low of $365.20 and a 1-year high of $557.00.

Chemed (NYSE:CHE – Get Free Report) last announced its earnings results on Tuesday, July 28th. The company reported $6.06 earnings per share for the quarter, topping the consensus estimate of $5.60 by $0.46. Chemed had a net margin of 10.60% and a return on equity of 31.77%. The company had revenue of $673.25 million during the quarter, compared to analyst estimates of $665.04 million. During the same quarter last year, the firm posted $4.27 earnings per share. Chemed’s revenue was up 8.8% compared to the same quarter last year. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. On average, analysts expect that Chemed Corporation will post 23.18 EPS for the current year.

Chemed Increases Dividend The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 3rd. Shareholders of record on Monday, August 17th will be paid a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a yield of 0.5%. This is a boost from Chemed’s previous quarterly dividend of $0.60. The ex-dividend date is Monday, August 17th. Chemed’s payout ratio is currently 14.06%.

Chemed Profile (Free Report)

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.

Read More Five stocks we like better than Chemed Bloom Energy’s AI Surge Meets a Valuation Reality Check Target Is Winning Shoppers Back—Can the Rally Reach $180? IonQ’s Space Contract Points to a New Frontier for Quantum Investors Is Apple’s AI Strategy Smarter Than Skeptics Think?

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.

CINCINNATI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 70-cents per share on the Company’s capital stock, payable on September 3, 2026, to shareholders of record as of August 17, 2026. This is a 10-cent, or 17%, increase over the 60-cent dividend paid in June 2026. This represents the 221st consecutive quarterly dividend paid by Chemed in its 55 years as a public company.

Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation (www.chemed.com) operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation's largest provider of end-of-life hospice care and Roto-Rooter is the nation’s leading provider of plumbing and drain cleaning services.

Statements in this press release or in other Chemed communications may relate to future events or Chemed's future performance. Such statements are forward-looking statements and are based on present information Chemed has related to its existing business circumstances. Investors are cautioned that such forward-looking statements are subject to inherent risk that actual results may differ materially from such forward-looking statements. Further, investors are cautioned that Chemed does not assume any obligation to update forward-looking statements based on unanticipated events or changed expectations.

CONTACT:Michael D. Witzeman
(513) 762-6714  

Chemed Corporation (CHE) receives a Buy rating with a $632/share target, driven by activist pressure for a spin-off to eliminate the conglomerate discount. VITAS has successfully reengineered its patient mix, sharply reducing Medicare Cap penalties and driving 8.8% revenue growth and 18.2% Adjusted EBITDA margin in Q2. Roto-Rooter faces structural margin pressure from rising digital marketing costs, but B2B expansion and operational efficiencies are expected to support future growth.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.

It also includes access to the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.94% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Chemed (CHE - Free Report) Cincinnati, OH-based Chemed Corporation purchases, operates and divests subsidiaries engaged in diverse business activities. The company’s operating businesses are managed on a decentralized basis. Since its inception, Chemed has engaged in twelve significant acquisitions or divestitures of diverse business units.

CHE is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

Momentum investors should take note of this Medical stock. CHE has a Momentum Style Score of A, and shares are up 8.7% over the past four weeks.

For fiscal 2026, one analyst revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.58 to $25.00 per share. CHE boasts an average earnings surprise of +1.9%.

With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, CHE should be on investors' short list.

3 Recession-Ready Stocks That Thrive When the Economy SputtersChemed NYSE: CHE reported second-quarter 2026 results marked by stronger-than-expected performance at its VITAS hospice business, while Roto-Rooter delivered revenue growth but continued to face higher customer-acquisition costs.

President and Chief Executive Officer Kevin McNamara said consolidated revenue rose 8.8% from the prior-year quarter and adjusted diluted earnings per share increased 41.9%. The company generated more than $173 million in operating cash flow during the quarter, which McNamara said supports acquisitions and potential share repurchases.

Get Chemed alerts:

VITAS Exceeds Expectations VITAS Healthcare reported net revenue of $443.3 million, up 11.9% from the second quarter of 2025. The increase reflected 6.1% growth in days of care and an approximately 2.4% geographically weighted average Medicare reimbursement-rate increase, according to Chief Financial Officer Mike Witzeman.

Average daily census increased 6.1% to 23,687 patients, and total patient census surpassed 24,000 by the end of the quarter, a record for VITAS, said Joel Wherley, president and CEO of the subsidiary. Admissions totaled 19,125, up 9% year over year.

VITAS reported growth across several referral categories. Hospital-directed admissions and home-based admissions each rose 9%, while assisted-living-facility admissions increased 13.5%. Nursing-home admissions declined 8.6%.

The company continued to focus on maintaining a hospital-admission mix between 42% and 45% in its Florida Combined Program, which management views as appropriate for long-term stability of the patient base and Medicare Cap management. Hospital admissions represented 42.9% of total admissions in the Florida Combined Program during the quarter. Admissions from non-hospital pre-admission locations in the program increased 8.1%.

McNamara said the stronger admissions performance added $8.9 million of Medicare Cap cushion in Florida during the quarter. VITAS recorded no Medicare Cap billing limitation in the Florida Combined Program and does not expect one for the 2026 fiscal period, compared with a $16.4 million limitation in the second quarter of 2025.

VITAS accrued $500,000 in Medicare Cap billing limitation overall during the quarter, below management’s expectations, primarily due to improved admissions performance in California. Adjusted EBITDA excluding Medicare Cap was $80.6 million, up 20.6% year over year, and the corresponding margin was 18.2%.

Average revenue per patient day was $209.98, up 143 basis points from the prior-year period. VITAS’ average length of stay fell to 101.2 days from 137.1 days a year earlier, while median length of stay declined to 16 days from 20 days.

Wherley said VITAS maintained staffing below budgeted levels without impairing its ability to hire, retain caregivers or meet growth expectations. The company also cited progress in new Florida markets, with Marion, Pasco and Pinellas counties generating a combined 594 admissions during the quarter. Manatee County admitted its first patient during the period.

Higher VITAS Guidance Chemed increased its full-year outlook for VITAS following the segment’s first-half performance. The company now expects average daily census growth of 5.75% to 6.25%, compared with its previous forecast of 4.5% to 5.5%.

Revenue growth excluding Medicare Cap is now projected at 8.25% to 9.25%, versus prior guidance of 6.5% to 7.5%. Adjusted EBITDA margin excluding Medicare Cap is expected to be 19% to 19.5%, up from the previous 18% to 18.5% range. Expected full-year Medicare Cap billing limitation was reduced to $7 million from $9.5 million. During the question-and-answer session, Wherley said management believes VITAS’ current growth level is sustainable into 2027, citing its operational metrics and ability to adjust resources to market conditions. McNamara said the business historically generated low-double-digit net-income growth over the 21 years Chemed has owned VITAS.

Management also said it sees no indication of material reimbursement restructuring at this time, though it expects increased program-integrity oversight and a greater focus on quality measures in hospice. Wherley said the proposed 2027 national average rate increase was 2.4%, while VITAS’ expected increase is 1.9%; Florida’s rate increase is projected to be slightly more than 1% below the national average based on the company’s current mix.

Roto-Rooter Revenue Growth Meets Marketing Pressure Roto-Rooter’s commercial revenue increased 6.8% to $56.8 million, while residential revenue rose 1.7% to $159.1 million. Commercial business managers contributed to results: branches with a productive commercial business manager throughout the quarter posted approximately 13% commercial revenue growth, compared with a 1% decline in branches without one.

Water restoration revenue declined 6.7%, despite what management described as strong demand and high conversion rates. Witzeman said the average revenue per water-restoration job fell roughly 3.5% during the transition to centralized billing and collections, an improvement from an approximately 13% decline in the first quarter. Total write-offs improved by $1.3 million, while the centralization effort reduced staffing by about 20 employees from a year earlier.

Independent-contractor revenue declined 1.9%. Roto-Rooter’s adjusted EBITDA was $48.5 million, essentially flat year over year, while adjusted EBITDA margin declined 77 basis points to 21.1%.

The primary pressure came from lead generation. Total leads declined 1.6%, as free internet-search leads fell 13.1% and paid leads rose 7.3%. Paid leads accounted for about 59% of total leads, compared with 54% a year earlier, increasing marketing expense by approximately $3.1 million.

Management said it views the marketing environment as stable but does not expect a significant improvement. It is pursuing alternative lead sources, including commercial-business-manager referrals and its app, while emphasizing higher-value services such as excavation and water restoration.

Franchise Acquisitions and Earnings Outlook In June, Roto-Rooter acquired the territory and assets of franchise operations in South Texas, including Corpus Christi, for about $12 million. The territory will operate as an independent contractor and is not expected to contribute materially to revenue or income in the second half of 2026, but McNamara described it as a growth opportunity for 2027 and beyond.

Through the first six months of the year, Chemed spent $33.5 million repurchasing four franchises in strategically advantageous locations. Management said it expects additional franchise acquisition opportunities may arise.

Chemed maintained its full-year Roto-Rooter outlook, calling for revenue growth of 3% to 3.5% and adjusted EBITDA margin of 21.5% to 22.5%.

For 2026, Chemed forecast adjusted diluted earnings per share of $25 to $25.75, excluding non-cash stock-option expenses, tax benefits from stock-option exercises, litigation costs and other discrete items. The midpoint represents a 17.8% increase from 2025 adjusted EPS of $21.55, the company said.

About Chemed (NYSE:CHE)Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Chemed Right Now?Before you consider Chemed, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemed wasn't on the list.

While Chemed currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

CINCINNATI, July 28, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its second quarter ended June 30, 2026, versus the comparable prior-year period.

Results for Quarter Ended June 30, 2026

Consolidated operating results:

Revenue increased 8.8% to $673.3 millionGAAP Diluted Earnings-per-Share (EPS) of $5.13, an increase of 43.7%Adjusted Diluted EPS of $6.06, an increase of 41.9% VITAS segment operating results:

Net Patient Revenue of $443.3 million, an increase of 11.9%Average Daily Census (ADC) of 23,687, an increase of 6.1%Admissions of 19,125, an increase of 9.0%Net Income, excluding certain discrete items, of $61.3 million, an increase of 60.5%Adjusted EBITDA, excluding Medicare Cap, of $80.6 million, an increase of 20.6%Adjusted EBITDA margin, excluding Medicare Cap, of 18.2%, an increase of 196-basis points Roto-Rooter segment operating results:

Revenue of $229.9 million, an increase of 3.3%Net Income, excluding certain discrete items, of $33.8 million, essentially flatAdjusted EBITDA of $48.5 million, essentially flatAdjusted EBITDA margin of 21.1%, a decline of 77-basis points VITAS

VITAS net revenue was $443.3 million in the second quarter of 2026, which is an increase of 11.9% when compared to the prior-year period. This revenue increase is comprised primarily of a 6.1% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.4%. Acuity mix shift negatively impacted revenue growth 115-basis points in the quarter when compared to the prior-year period’s revenue and level-of-care mix. The combination of Medicare Cap and other contra revenue changes positively impacted revenue growth by 455-basis points.

Total VITAS admissions increased 9.0% in the second quarter of 2026 compared to the second quarter of 2025.

In the second quarter of 2026, VITAS accrued $500,000 in Medicare Cap billing limitation. This compares to the Medicare Cap billing limitation recorded in the second quarter of 2025 of $16.4 million. No Medicare Cap billing limitation was recorded in the second quarter of 2026 for the Florida combined program, and none is anticipated for the 2026 fiscal period.

Of VITAS’ 33 Medicare provider numbers, 22 provider numbers have an anticipated full-year Medicare Cap cushion of 10% or greater, seven provider numbers have a cushion between 0% and 10%, and four provider numbers have a Medicare Cap billing limitation totaling $7.0 million.

Average revenue per patient per day in the second quarter of 2026 was $209.98 which is 143-basis points above the prior-year period. Reimbursement for routine home care and high-acuity care averaged $188.62 and $1,152.14, respectively. During the quarter, high-acuity days-of-care were 2.2% of total days of care, a decline of 24-basis points when compared to the prior-year quarter.

The second quarter 2026 gross margin, excluding Medicare Cap, was 23.9%, a 164-basis point increase from the same period of 2025. Selling, general and administrative expenses were $26.1 million in the second quarter of 2026 compared to $25.1 million in the prior- year quarter.

Adjusted EBITDA, excluding Medicare Cap, totaled $80.6 million in the quarter, an increase of 20.6% when compared to the prior-year period. Adjusted EBITDA margin in the quarter, excluding Medicare Cap, was 18.2%.

Roto-Rooter

Roto-Rooter generated quarterly revenue of $229.9 million in the second quarter of 2026, an increase of 3.3%, when compared to the prior-year quarter.

Roto-Rooter branch commercial revenue in the quarter totaled $56.8 million, an increase of 6.8% from the prior-year period. This aggregate commercial revenue change consisted of plumbing increasing 11.9%, drain cleaning increasing 6.9%, water restoration increasing 3.7% and excavation increasing 2.3%.

Roto-Rooter branch residential revenue in the quarter totaled $159.1 million, an increase of 1.7%, over the prior-year period. This aggregate residential revenue change consisted of excavation increasing 11.1%, plumbing increasing 3.3%, and drain cleaning increasing 1.3%, offset by a decline in water restoration of 6.7%.

In the second quarter of 2026, revenue from independent contractors was $17.1 million which is a decline of 1.9% as compared to the same period of 2025.

Roto-Rooter’s second quarter 2026 gross margin was 50.4%. This compares to the prior-year quarter’s gross margin of 49.0%. Roto-Rooter’s selling, general and administrative expenses were $67.4 million in the quarter, which is an increase of 11.3% compared to the second quarter of 2025.

Adjusted EBITDA in the second quarter of 2026 totaled $48.5 million, essentially flat when compared to the second quarter of 2025. The Adjusted EBITDA margin in the quarter was 21.1% which represents a 77-basis point decline from the second quarter of 2025.

Chemed Consolidated

As of June 30, 2026, Chemed had total cash and cash equivalents of $40.2 million and $140.0 million in long-term debt.

In April 2026, Chemed entered into a new five-year $450 million Amended and Restated Credit Agreement (Credit Agreement). This Credit Agreement consists of a $450 million revolving line of credit and a $250 million expansion feature. The interest rate on this Credit Agreement has a floating rate that is currently SOFR plus 100-basis points. There is approximately $262.7 million undrawn borrowing capacity under the Credit Agreement after excluding $47.3 million for Letters of Credit.

During the quarter, the Company repurchased 210,000 shares of Chemed stock for $89.8 million which equates to a cost per share of $427.81. Over the trailing 12-months, the Company has repurchased 1,517,500 shares of Chemed stock at an average price of $423.63 per share. This equates to a reduction in outstanding Chemed shares of approximately 10.5% over that period. As of June 30, 2026, there was approximately $139.8 million of remaining share repurchase authorization under its plan.

Guidance Update

Although, historically, we do not give quarterly updates, our guidance was revised in conjunction with the first quarter 2026 earnings release due to the materially improved performance of VITAS, coupled with the level of share repurchases. We have updated the guidance again mainly to continue our normal, historical cadence of updating expectations at the mid-year earnings release. Barring any unusual developments, updating guidance once per year in conjunction with our second quarter press release is our on-going expectation. Further operational detail will be provided during the investor conference call.

VITAS’ initiatives to return to a normal growth pattern after managing the 2025 Medicare Cap issue progressed more quickly than originally anticipated and continue to provide higher than expected growth in the business. The following shows the updated key guidance metrics compared to the guidance metrics provided in the first quarter 2026 earnings release:

  Revised Range  Range Q1 ReleaseADC growth 5.75% - 6.25% 4.5% - 5.5%     Revenue growth, excluding Medicare Cap 8.25% - 9.25% 6.5% - 7.5%     Medicare Cap billing limitation (full year) $7,000 $9,500     EBITDA margin, excluding Medicare Cap 19.0% - 19.5% 18.0% - 18.5%
Roto-Rooter performed in-line with our expectations and therefore, full year guidance for the segment remains unchanged. Full year anticipated revenue growth is 3.0% to 3.5%. Estimated adjusted EBITDA margin is 21.5% to 22.5%.

Based on the above, full-year 2026 earnings per diluted share, excluding non-cash expenses for stock options, tax benefits from stock option exercises, costs related to litigation and other discrete items, are estimated to be in the range of $25.00 to $25.75. This compares to the guidance given in conjunction with the first quarter of 2026 press release of $24.00 to $24.75 per diluted share. The mid-point of the revised guidance represents a 17.8% increase from 2025 adjusted earnings per diluted share of $21.55. The revised guidance assumes an effective corporate tax rate on adjusted earnings of 24.5% and a diluted share count of 13.5 million shares.  

Conference Call

As previously disclosed, Chemed will host a conference call and webcast at 10 a.m., ET, on Wednesday July 29, 2026, to discuss the company's quarterly results and to provide an update on its business. Participants may access a live webcast of the conference call through the investor relations section of Chemed’s website, Investor Relations Home | Chemed Corporation or the hosting website https://edge.media-server.com/mmc/p/u8u2qjst.

Participants may also register via teleconference at:
https://register-conf.media-server.com/register/BI55b09312fbd04f76b526dfcc5f7e174e.

Once registration is completed, participants will be provided with a dial-in number containing a personalized conference code to access the call. All participants are instructed to dial-in 15 minutes prior to the start time.

A taped replay of the conference call will be available beginning approximately two hours after the call's conclusion. You may access the replay via webcast through the investor relations section of Chemed’s website.

Chemed operates in the healthcare field through its VITAS Healthcare Corporation subsidiary. VITAS provides daily hospice services to patients with severe, life-limiting illnesses. This type of care is focused on making the terminally ill patient's final days as comfortable and pain-free as possible.

Chemed operates in the residential and commercial plumbing and drain cleaning industry under the brand name Roto-Rooter. Roto-Rooter provides plumbing, drain cleaning, and water cleanup services through company-owned branches, independent contractors and franchisees in the United States and Canada. Roto-Rooter also has licensed master franchisees in the republics of Indonesia and Singapore, and the Philippines.

This press release contains information about Chemed’s EBITDA, Adjusted EBITDA, and Adjusted Diluted EPS, which are not measures derived in accordance with GAAP and which exclude components that are important to understanding Chemed’s financial performance. In reporting its operating results, Chemed provides EBITDA, Adjusted EBITDA and Adjusted Diluted EPS measures to help investors and others evaluate the Company’s operating results, compare its operating performance with that of similar companies that have different capital structures and evaluate its ability to meet its future debt service, capital expenditures and working capital requirements. Chemed’s management similarly uses EBITDA, Adjusted EBITDA, and Adjusted Diluted EPS to assist it in evaluating the performance of the Company across fiscal periods and in assessing how its performance compares to its peer companies. These measures also help Chemed’s management to estimate the resources required to meet Chemed’s future financial obligations and expenditures. Chemed’s EBITDA, Adjusted EBITDA and Adjusted Diluted EPS should not be considered in isolation or as a substitute for comparable measures calculated and presented in accordance with GAAP. We calculated Adjusted EBITDA Margin by dividing Adjusted EBITDA by service revenue and sales. A reconciliation of Chemed’s net income to its EBITDA, Adjusted EBITDA and Adjusted Diluted EPS is presented in the tables following the text of this press release.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 REGARDING FORWARD-LOOKING INFORMATION

Statements in this press release contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods and are based upon assumptions subject to certain known and unknown risks, uncertainties, contingencies and other factors, including, but not limited to, the impact of laws and regulations on Chemed’s operations, including Medicare Cap and Medicare reimbursement rates, Chemed’s estimates of the effect of Medicare Cap on VITAS’ revenues and future prospects, Chemed’s expectations regarding VITAS’ patient mix and Chemed’s expectations regarding demand for Roto-Rooter’s services.

Because forward looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Chemed’s control. Chemed’s actual results and financial condition may differ materially from those indicated in the forward-looking statements included in this press release, including as a result of the risks described above and those described in the Chemed’s Annual Report on Form 10-K for the year ended December 31, 2025 and in its Quarterly Reports filed in 2026. Any forward-looking statement made by Chemed in this press release is based only on information currently available to Chemed and speaks only as of the date on which it is made. Chemed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

CONTACT:
Michael D. Witzeman
(513) 762-6714

CHEMED CORPORATION AND SUBSIDIARY COMPANIESCONSOLIDATED STATEMENTS OF INCOME(in thousands, except per share data)(unaudited)               Three Months Ended June 30, Six Months Ended June 30,  2026
 2025
 2026
 2025
Service revenues and sales $673,251  $618,798  $1,330,764   1,265,741 Cost of services provided and goods sold  451,780   434,105   893,529   864,635 Selling, general and administrative expenses (aa)  115,203   100,323   229,524   205,910 Depreciation  14,267   13,689   28,570   27,134 Amortization  2,719   2,571   5,289   5,143 Other operating expense  78   26   70   77 Total costs and expenses  584,047   550,714   1,156,982   1,102,899 Income from operations  89,204   68,084   173,782   162,842 Interest expense  (1,789)  (443)  (2,301)  (772)Other income--net (bb)  3,914   3,474   8,688   4,719 Income before income taxes  91,329   71,115   180,169   166,789 Income taxes  (23,626)  (18,622)  (46,164)  (42,539)Net income $67,703  $52,493  $134,005  $124,250 Earnings Per Share            Net income $5.14  $3.60  $9.98  $8.51 Average number of shares outstanding  13,174   14,591   13,423   14,606 Diluted Earnings Per Share            Net income $5.13  $3.57  $9.97  $8.43 Average number of shares outstanding  13,199   14,703   13,442   14,733              (aa)    Selling, general and administrative ("SG&A") expenses comprise (in thousands):               Three Months Ended June 30, Six Months Ended June 30,  2026
 2025
 2026
 2025
SG&A expenses before long-term incentive compensation            and the impact of market value adjustments related to            deferred compensation plans $109,256  $98,552  $218,187  $202,312 Market value adjustments related to deferred             compensation trusts  3,699   918   7,584   88 Long-term incentive compensation  2,248   853   3,753   3,510 Total SG&A expenses $115,203  $100,323  $229,524  $205,910              (bb)    Other income--net comprises (in thousands):        Three Months Ended June 30, Six Months Ended June 30,  2026
 2025
 2026
 2025
             Market value adjustments related to deferred            compensation trusts $3,699  $918  $7,584  $88 Interest income  214   2,555   1,104   4,631 Other  1   1   -   - Total other income--net $3,914  $3,474  $8,688  $4,719               CHEMED CORPORATION AND SUBSIDIARY COMPANIESCONSOLIDATED BALANCE SHEETS(in thousands, except per share data)(unaudited)         June 30,  2026
 2025
Assets      Current assets      Cash and cash equivalents $40,222  $249,904 Accounts receivable less allowances  188,634   184,880 Inventories  7,630   9,148 Prepaid income taxes  17,646   14,239 Prepaid expenses  37,103   33,206 Total current assets  291,235   491,377 Investments of deferred compensation plans held in trust  148,153   129,560 Properties and equipment, at cost less accumulated depreciation  208,499   202,281 Lease right of use asset  142,535   131,948 Identifiable intangible assets less accumulated amortization  78,601   87,360 Goodwill  699,398   666,996 Other assets  11,164   8,325 Total Assets $1,579,585  $1,717,847 Liabilities      Current liabilities      Accounts payable $84,713  $50,864 Accrued insurance  72,455   66,888 Accrued compensation  63,794   54,688 Short-term lease liability  41,277   43,700 Other current liabilities  57,607   47,746 Total current liabilities  319,846   263,886 Deferred income taxes  15,050   12,703 Deferred compensation liabilities  146,986   127,699 Long-term debt  140,000   - Long-term lease liability  113,516   101,861 Other liabilities  13,677   13,213 Total Liabilities  749,075   519,362 Stockholders' Equity      Capital stock  37,613   37,593 Paid-in capital  1,617,125   1,576,165 Retained earnings  3,073,331   2,831,540 Treasury stock, at cost  (3,900,000)  (3,249,115)Deferred compensation payable in Company stock  2,441   2,302 Total Stockholders' Equity  830,510   1,198,485 Total Liabilities and Stockholders' Equity $1,579,585  $1,717,847         CHEMED CORPORATION AND SUBSIDIARY COMPANIESCONSOLIDATED STATEMENTS OF CASH FLOWS(in thousands)(unaudited)         For the Six Months Ended June 30,  2026
 2025
Cash Flows from Operating Activities      Net income $134,005  $124,250 Adjustments to reconcile net income to net cash provided      by operating activities:      Depreciation and amortization  33,859   32,277 Stock option expense  18,302   18,307 Benefit for deferred income taxes  (4,262)  (13,243)Noncash long-term incentive compensation  3,633   3,273 Noncash directors' compensation  1,191   1,123 Legal settlements  548   - Amortization of debt issuance costs  163   160 Changes in operating assets and liabilities, excluding      amounts acquired in business combinations:      Increase in accounts receivable  (6,716)  (13,466)Increase in inventories  (87)  (955)Increase in prepaid expenses  (10,285)  (7,232)Increase/(decrease) in accounts payable and      other current liabilities  9,174   (12,449)Change in current income taxes  (8,985)  (10,764)Net change in lease assets and liabilities  292   (72)(Increase)/decrease in other assets  (9,489)  48,426 Increase in other liabilities  11,191   1,521 Other sources  498   194 Net cash provided by operating activities  173,032   171,350 Cash Flows from Investing Activities      Business combinations, net of cash acquired  (33,540)  (225)Capital expenditures  (32,639)  (29,088)Proceeds from sale of fixed assets  422   480 Other uses  (270)  (322)Net cash used by investing activities  (66,027)  (29,155)Cash Flows from Financing Activities      Proceeds from revolving line of credit  491,480   - Payments on revolving line of credit  (351,480)  - Purchases of treasury stock  (287,521)  (76,168)Change in cash overdrafts payable  23,305   309 Dividends paid  (16,049)  (14,542)Proceeds from exercise of stock options  2,731   27,152 Capital stock surrendered to pay taxes on stock-based compensation  (1,482)  (8,484)Debt issuance costs  (1,349)  - Other (uses)/sources  (933)  1,092 Net cash used by financing activities  (141,298)  (70,641)(Decrease)/increase in Cash and Cash Equivalents  (34,293)  71,554 Cash and cash equivalents at beginning of year  74,515   178,350 Cash and cash equivalents at end of period $40,222  $249,904         CHEMED CORPORATION AND SUBSIDIARY COMPANIESCONSOLIDATING STATEMENTS OF INCOMEFOR THE THREE MONTHS ENDED JUNE 30, 2026 AND 2025(in thousands)(unaudited)        Chemed  VITAS Roto-Rooter Corporate Consolidated2026 (a)            Service revenues and sales $443,341  $229,910  $-  $673,251 Cost of services provided and goods sold  337,691   114,089   -   451,780 Selling, general and administrative expenses  26,105   67,373   21,725   115,203 Depreciation  5,781   8,474   12   14,267 Amortization  27   2,692   -   2,719 Other operating expense  28   50   -   78 Total costs and expenses  369,632   192,678   21,737   584,047 Income/(loss) from operations  73,709   37,232   (21,737)  89,204 Interest expense  (54)  (185)  (1,550)  (1,789)Intercompany interest income/(expense)  6,480   4,575   (11,055)  - Other income—net  66   10   3,838   3,914 Income/(loss) before income taxes  80,201   41,632   (30,504)  91,329 Income taxes  (19,290)  (9,719)  5,383   (23,626)Net income/(loss) $60,911  $31,913  $(25,121) $67,703              2025 (b)            Service revenues and sales $396,201  $222,597  $-  $618,798 Cost of services provided and goods sold  320,644   113,461   -   434,105 Selling, general and administrative expenses  25,085   60,536   14,702   100,323 Depreciation  5,314   8,363   12   13,689 Amortization  26   2,545   -   2,571 Other operating expense/(income)  55   (29)  -   26 Total costs and expenses  351,124   184,876   14,714   550,714 Income/(loss) from operations  45,077   37,721   (14,714)  68,084 Interest expense  (47)  (129)  (267)  (443)Intercompany interest income/(expense)  5,454   3,970   (9,424)  - Other income—net  61   23   3,390   3,474 Income/(loss) before income taxes  50,545   41,585   (21,015)  71,115 Income taxes  (12,326)  (9,671)  3,375   (18,622)Net income/(loss) $38,219  $31,914  $(17,640) $52,493                           The "Footnotes to Financial Statements" are integral parts of this financial information.             CHEMED CORPORATION AND SUBSIDIARY COMPANIESCONSOLIDATING STATEMENTS OF INCOMEFOR THE SIX MONTHS ENDED JUNE 30, 2026 AND 2025(in thousands)(unaudited)                  Chemed  VITAS Roto-Rooter Corporate Consolidated2026 (a)            Service revenues and sales $863,358  $467,406  $-  $1,330,764 Cost of services provided and goods sold  663,157   230,372   -   893,529 Selling, general and administrative expenses  52,213   135,302   42,009   229,524 Depreciation  11,693   16,853   24   28,570 Amortization  53   5,236   -   5,289 Other operating expense/(income)  80   (9)  (1)  70 Total costs and expenses  727,196   387,754   42,032   1,156,982 Income/(loss) from operations  136,162   79,652   (42,032)  173,782 Interest expense  (104)  (321)  (1,876)  (2,301)Intercompany interest income/(expense)  12,717   9,088   (21,805)  - Other income—net  161   25   8,502   8,688 Income/(loss) before income taxes  148,936   88,444   (57,211)  180,169 Income taxes  (35,818)  (20,747)  10,401   (46,164)Net income/(loss) $113,118  $67,697  $(46,810) $134,005              2025 (b)            Service revenues and sales $803,600  $462,141  $-  $1,265,741 Cost of services provided and goods sold  633,451   231,184   -   864,635 Selling, general and administrative expenses  51,624   123,184   31,102   205,910 Depreciation  10,509   16,601   24   27,134 Amortization  52   5,091   -   5,143 Other operating expense/(income)  119   (42)  -   77 Total costs and expenses  695,755   376,018   31,126   1,102,899 Income/(loss) from operations  107,845   86,123   (31,126)  162,842 Interest expense  (95)  (261)  (416)  (772)Intercompany interest income/(expense)  10,750   7,900   (18,650)  - Other income—net  110   32   4,577   4,719 Income/(loss) before income taxes  118,610   93,794   (45,615)  166,789 Income taxes  (30,361)  (21,936)  9,758   (42,539)Net income/(loss) $88,249  $71,858  $(35,857) $124,250                           The "Footnotes to Financial Statements" are integral parts of this financial information.                           CHEMED CORPORATION AND SUBSIDIARY COMPANIESCONSOLIDATING SUMMARIES OF EBITDAFOR THREE MONTHS ENDED JUNE 30, 2026 AND 2025(in thousands)(unaudited)        Chemed  VITAS Roto-Rooter Corporate Consolidated2026            Net income/(loss) $60,911  $31,913  $(25,121) $67,703 Add/(deduct):            Interest expense  54   185   1,550   1,789 Income taxes  19,290   9,719   (5,383)  23,626 Depreciation  5,781   8,474   12   14,267 Amortization  27   2,692   -   2,719 EBITDA  86,063   52,983   (28,942)  110,104 Add/(deduct):            Intercompany interest expense/(income)  (6,480)  (4,575)  11,055   - Interest income  (66)  (10)  (138)  (214)Stock option expense  -   -   9,052   9,052 Long-term incentive compensation  -   -   2,248   2,248 Legal settlements  548   -   -   548 Acquisition expense  8   60   -   68 Adjusted EBITDA $80,073  $48,458  $(6,725) $121,806              2025            Net income/(loss) $38,219  $31,914  $(17,640) $52,493 Add/(deduct):            Interest expense  47   129   267   443 Income taxes  12,326   9,671   (3,375)  18,622 Depreciation  5,314   8,363   12   13,689 Amortization  26   2,545   -   2,571 EBITDA  55,932   52,622   (20,736)  87,818 Add/(deduct):            Intercompany interest expense/(income)  (5,454)  (3,970)  9,424   - Interest income  (61)  (23)  (2,472)  (2,556)Stock option expense  -   -   9,216   9,216 Long-term incentive compensation  -   -   853   853 Adjusted EBITDA $50,417  $48,629  $(3,715) $95,331              The "Footnotes to Financial Statements" are integral parts of this financial information.             CHEMED CORPORATION AND SUBSIDIARY COMPANIESCONSOLIDATING SUMMARIES OF EBITDAFOR THE SIX MONTHS ENDED JUNE 30, 2026 AND 2025(in thousands)(unaudited)           Chemed  VITAS Roto-Rooter Corporate Consolidated2026            Net income/(loss) $113,118  $67,697  $(46,810) $134,005 Add/(deduct):            Interest expense  104   321   1,876   2,301 Income taxes  35,818   20,747   (10,401)  46,164 Depreciation  11,693   16,853   24   28,570 Amortization  53   5,236   -   5,289 EBITDA  160,786   110,854   (55,311)  216,329 Add/(deduct):            Intercompany interest expense/(income)  (12,717)  (9,088)  21,805   - Interest income  (162)  (25)  (917)  (1,104)Stock option expense  -   -   18,302   18,302 Long-term incentive compensation  -   -   3,753   3,753 Legal settlements  548   -   -   548 Acquisition expense  8   226   -   234 Adjusted EBITDA $148,463  $101,967  $(12,368) $238,062 2025            Net income/(loss) $88,249  $71,858  $(35,857) $124,250 Add/(deduct):            Interest expense  95   261   416   772 Income taxes  30,361   21,936   (9,758)  42,539 Depreciation  10,509   16,601   24   27,134 Amortization  52   5,091   -   5,143 EBITDA  129,266   115,747   (45,175)  199,838 Add/(deduct):            Intercompany interest expense/(income)  (10,750)  (7,900)  18,650   - Interest income  (110)  (33)  (4,489)  (4,632)Stock option expense  -   -   18,307   18,307 Long-term incentive compensation  -   -   3,510   3,510 Adjusted EBITDA $118,406  $107,814  $(9,197) $217,023              The "Footnotes to Financial Statements" are integral parts of this financial information.              CHEMED CORPORATION AND SUBSIDIARY COMPANIESRECONCILIATION OF ADJUSTED NET INCOME(in thousands, except per share data)(unaudited)                    Three Months Ended June 30, Six Months Ended June 30,  2026
 2025
 2026
 2025
Net income as reported $67,703  $52,493  $134,005  $124,250 Add/(deduct) pre-tax cost of:            Stock option expense  9,052   9,216   18,302   18,307 Amortization of reacquired franchise rights  2,352   2,352   4,704   4,704 Long-term incentive compensation  2,248   853   3,753   3,510 Legal settlements  548   -   548   - Acquisition expense  68   -   234   - Add/(deduct) tax impacts:            Tax impact of the above pre-tax adjustments (1)  (2,377)  (2,143)  (4,626)  (4,462)Excess tax expenses/(benefits) on stock compensation  445   (50)  501   (513)Adjusted net income $80,039  $62,721  $157,421  $145,796              Diluted Earnings Per Share As Reported            Net income $5.13  $3.57  $9.97  $8.43 Average number of shares outstanding  13,199   14,703   13,442   14,733              Adjusted Diluted Earnings Per Share            Adjusted net income $6.06  $4.27  $11.71  $9.90 Average number of shares outstanding  13,199   14,703   13,442   14,733              (1) The tax impact of pre-tax adjustments was calculated using the effective tax rate of the operating unit for which each adjustment is associated.             The "Footnotes to Financial Statements" are integral parts of this financial information.              CHEMED CORPORATION AND SUBSIDIARY COMPANIESOPERATING STATISTICS FOR VITAS SEGMENT(unaudited) Three Months Ended June 30,  For the Six Months Ended June 30,OPERATING STATISTICS2026
 2025
  2026
 2025
Net revenue ($000) (c)            Homecare$391,348  $358,042   $762,438  $709,608 Inpatient 35,673   33,023    71,599   67,045 Continuous care 19,396   23,640    37,530   48,276 Other 6,206   5,747    11,783   11,092 Subtotal$452,623  $420,452   $883,350  $836,021 Room and board, net (3,938)  (3,892)   (7,196)  (7,417)Contractual allowances (4,844)  (3,984)   (9,921)  (6,304)Medicare cap allowance (500)  (16,375)   (2,875)  (18,700)Net Revenue$443,341  $396,201   $863,358  $803,600 Net revenue as a percent of total before Medicare cap allowance            Homecare 86.5%  85.2%   86.4%  84.9%Inpatient 7.9   7.9    8.1   8.0 Continuous care 4.3   5.6    4.2   5.8 Other 1.3   1.3    1.3   1.3 Subtotal 100.0   100.0    100.0   100.0 Room and board, net (0.9)  (0.9)   (0.9)  (0.9)Contractual allowances (1.1)  (0.9)   (1.1)  (0.8)Medicare cap allowance (0.1)  (3.9)   (0.3)  (2.2)Net Revenue 97.9%  94.3%   97.7%  96.1%Days of care            Homecare 1,792,360   1,662,455    3,483,979   3,295,024 Nursing home 303,053   307,158    597,871   614,266 Respite 12,307   11,440    23,182   21,435 Subtotal routine homecare and respite 2,107,720   1,981,053    4,105,032   3,930,725 Inpatient 29,703   28,213    60,177   57,917 Continuous care 18,094   21,647    35,382   44,267 Total 2,155,517   2,030,913    4,200,591   4,032,909              Number of days in relevant time period 91   91    181   181 Average daily census ("ADC") (days)            Homecare 19,697   18,269    19,249   18,205 Nursing home 3,330   3,375    3,303   3,394 Respite 135   126    128   118 Subtotal routine homecare and respite 23,162   21,770    22,680   21,717 Inpatient 326   310    333   320 Continuous care 199   238    195   244 Total 23,687   22,318    23,208   22,281              Total Admissions 19,125   17,545    38,519   35,684 Total Discharges 18,167   17,845    36,704   35,583 Average length of stay (days) 101.2   137.1    101.9   127.9 Median length of stay (days) 16.0   20.0    15.0   18.0              ADC by major diagnosis            Cerebro 44.2%  44.4%   44.4%  44.6%Neurological 11.1   12.1    11.2   12.2 Cancer 9.5   9.7    9.5   9.6 Cardio 16.6   16.2    16.5   16.1 Respiratory 8.0   7.5    7.8   7.3 Other 10.6   10.1    10.6   10.2 Total 100.0%  100.0%   100.0%  100.0%Admissions by major diagnosis            Cerebro 27.3%  26.7%   27.1%  27.6%Neurological 7.1   7.2    7.0   6.8 Cancer 24.7   26.6    24.1   25.6 Cardio 15.2   14.9    15.5   15.0 Respiratory 11.8   10.7    12.1   11.1 Other 13.9   13.9    14.2   13.9 Total 100.0%  100.0%   100.0%  100.0%             Estimated uncollectible accounts as a percent of revenues 0.7%  1.0%   1.1%  0.8%             Accounts receivable --            Days of revenue outstanding-excluding unapplied Medicare payments39.7   37.5    n.a.  n.a.Days of revenue outstanding-including unapplied Medicare payments26.9   26.9    n.a.  n.a.              CHEMED CORPORATION AND SUBSIDIARY COMPANIESFOOTNOTES TO FINANCIAL STATEMENTSFOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2026 AND 2025(unaudited)              (a)Included in the results of operations for 2026 are the following significant credits/(charges) which may not be indicative of ongoing operations (in thousands):               Three Months Ended June 30, 2026   VITAS Roto-Rooter Corporate Consolidated               Stock option expense $-  $-  $(9,052) $(9,052) Amortization of reacquired franchise agreements  -   (2,352)  -   (2,352) Long-term incentive compensation  -   -   (2,248)  (2,248) Legal settlements  (548)  -   -   (548) Acquisition expense  (8)  (60)  -   (68) Pretax impact on earnings  (556)  (2,412)  (11,300)  (14,268) Excess tax expenses on stock compensation  -   -   (445)  (445) Income tax benefit on the above  135   562   1,680   2,377  After-tax impact on earnings $(421) $(1,850) $(10,065) $(12,336)                 Six Months Ended June 30, 2026   VITAS Roto-Rooter Corporate Consolidated               Stock option expense $-  $-  $(18,302) $(18,302) Amortization of reacquired franchise agreements  -   (4,704)  -   (4,704) Long-term incentive compensation  -   -   (3,753)  (3,753) Legal settlements  (548)  -   -   (548) Acquisition expense  (8)  (226)  -   (234) Pretax impact on earnings  (556)  (4,930)  (22,055)  (27,541) Excess tax expenses on stock compensation  -   -   (501)  (501) Income tax benefit on the above  135   1,149   3,342   4,626  After-tax impact on earnings $(421) $(3,781) $(19,214) $(23,416)              (b)Included in the results of operations for 2025 are the following significant credits/(charges) which may not be indicative of ongoing operations (in thousands):               Three Months Ended June 30, 2025   VITAS Roto-Rooter Corporate Consolidated               Stock option expense $-  $-  $(9,216) $(9,216) Amortization of reacquired franchise agreements  -   (2,352)  -   (2,352) Long-term incentive compensation  -   -   (853)  (853) Pretax impact on earnings  -   (2,352)  (10,069)  (12,421) Excess tax benefits on stock compensation  -   -   50   50  Income tax benefit on the above  -   546   1,597   2,143  After-tax impact on earnings $-  $(1,806) $(8,422) $(10,228)                 Six Months Ended June 30, 2025   VITAS Roto-Rooter Corporate Consolidated               Stock option expense $-  $-  $(18,307) $(18,307) Amortization of reacquired franchise agreements  -   (4,704)  -   (4,704) Long-term incentive compensation  -   -   (3,510)  (3,510) Pretax impact on earnings  -   (4,704)  (21,817)  (26,521) Excess tax benefits on stock compensation  -   -   513   513  Income tax benefit on the above  -   1,091   3,371   4,462  After-tax impact on earnings $-  $(3,613) $(17,933) $(21,546)                            (c)VITAS has 13 large (greater than 450 ADC), 24 medium (greater than 200 but less than 450 ADC) and 23 small (less than 200 ADC) hospice programs. Of Vitas' 33 Medicare provider numbers, for the current cap year, 22 provider numbers have a Medicare cap cushion of greater than 10%, seven provider numbers have a Medicare cap cushion between 0% and 10%, and four provider numbers have a Medicare cap liability.  

Posted by Defense World Staff on Jul 27th, 2026

Entropy Technologies LP grew its holdings in shares of Chemed Corporation (NYSE:CHE – Free Report) by 491.7% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,195 shares of the company’s stock after buying an additional 5,979 shares during the quarter. Entropy Technologies LP owned 0.05% of Chemed worth $2,718,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in CHE. Geneos Wealth Management Inc. boosted its stake in Chemed by 330.4% during the 1st quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock valued at $61,000 after purchasing an additional 76 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its stake in shares of Chemed by 67.0% in the second quarter. Arrowstreet Capital Limited Partnership now owns 11,365 shares of the company’s stock worth $5,534,000 after purchasing an additional 4,560 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Chemed in the second quarter worth approximately $579,000. Brown Advisory Inc. lifted its holdings in shares of Chemed by 36.9% in the second quarter. Brown Advisory Inc. now owns 549 shares of the company’s stock valued at $267,000 after purchasing an additional 148 shares in the last quarter. Finally, Cerity Partners LLC lifted its holdings in shares of Chemed by 237.7% in the second quarter. Cerity Partners LLC now owns 4,451 shares of the company’s stock valued at $2,165,000 after purchasing an additional 3,133 shares in the last quarter. 95.85% of the stock is owned by institutional investors.

Analyst Ratings Changes Several research analysts recently issued reports on CHE shares. Bank of America lifted their target price on Chemed from $450.00 to $510.00 and gave the company a “neutral” rating in a research report on Thursday, July 9th. Royal Bank Of Canada increased their price target on Chemed from $422.00 to $436.00 and gave the company a “sector perform” rating in a research report on Monday, April 27th. Zacks Research upgraded Chemed from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Wall Street Zen downgraded shares of Chemed from a “buy” rating to a “hold” rating in a report on Monday, June 8th. Finally, Weiss Ratings upgraded shares of Chemed from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, July 17th. One investment analyst has rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $480.25.

Get Our Latest Report on CHE

Insiders Place Their Bets In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the business’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $421.13, for a total value of $842,260.00. Following the sale, the chief executive officer directly owned 90,219 shares in the company, valued at $37,993,927.47. The trade was a 2.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Andrea R. Lindell sold 1,347 shares of the company’s stock in a transaction on Tuesday, June 9th. The shares were sold at an average price of $447.33, for a total value of $602,553.51. Following the transaction, the director directly owned 4,578 shares in the company, valued at $2,047,876.74. This represents a 22.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 3.33% of the company’s stock.

Chemed Stock Down 0.2% Chemed stock opened at $510.28 on Monday. The firm has a 50 day moving average price of $458.59 and a 200-day moving average price of $433.61. The company has a quick ratio of 0.83, a current ratio of 0.85 and a debt-to-equity ratio of 0.11. Chemed Corporation has a twelve month low of $365.20 and a twelve month high of $517.74. The company has a market capitalization of $6.77 billion, a P/E ratio of 27.81, a P/E/G ratio of 1.88 and a beta of 0.52.

Chemed (NYSE:CHE – Get Free Report) last posted its quarterly earnings results on Thursday, April 23rd. The company reported $5.65 EPS for the quarter, topping analysts’ consensus estimates of $5.30 by $0.35. Chemed had a net margin of 10.23% and a return on equity of 27.18%. The company had revenue of $657.51 million for the quarter, compared to analysts’ expectations of $659.22 million. During the same quarter in the previous year, the firm posted $5.63 EPS. Chemed’s revenue was up 1.6% on a year-over-year basis. As a group, equities analysts predict that Chemed Corporation will post 22.67 EPS for the current year.

Chemed Dividend Announcement The company also recently announced a quarterly dividend, which was paid on Tuesday, June 16th. Shareholders of record on Thursday, May 28th were given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend was Thursday, May 28th. Chemed’s dividend payout ratio (DPR) is currently 13.08%.

About Chemed (Free Report)

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.

Featured Articles Five stocks we like better than Chemed RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade? These 4 Earnings Reports Expose the Market’s Growing Economic Divide Broadcom May Be the Biggest Winner From Alphabet’s Earnings Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBradley Foster & Sargent Inc. CT Has $2.30 Million Stake in APi Group Corporation $APG

NEXT HEADLINE »Impinj, Inc. $PI Shares Acquired by Fifth Third Bancorp

CINCINNATI, July 01, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the second quarter ended June 30, 2026, on Tuesday, July 28, 2026, following the close of trading on the New York Stock Exchange.

Chemed will host a conference call and webcast at 10 a.m., ET, on Wednesday, July 29, 2026, to discuss the company's quarterly results and to provide an update on its business.

Participants may access a live webcast of the conference call through the investor relations section of Chemed’s website, Investor Relations Home | Chemed Corporation or the hosting website https://edge.media-server.com/mmc/p/u8u2qjst.

Participants may also register via teleconference at https://register-conf.media-server.com/register/BI55b09312fbd04f76b526dfcc5f7e174e.

Once registration is completed, participants will be provided with a dial-in number containing a personalized conference code to access the call. All participants are instructed to dial-in 15 minutes prior to the start time.

A taped replay of the conference call will be available beginning approximately two hours after the call's conclusion. You may access the replay via webcast through the investor relations section of Chemed’s website.

Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation (www.chemed.com) operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation's largest provider of end-of-life hospice care and Roto-Rooter is the nation’s leading provider of plumbing and drain cleaning services.

Statements in this press release or in other Chemed communications may relate to future events or Chemed's future performance. Such statements are forward-looking statements and are based on present information Chemed has related to its existing business circumstances. Investors are cautioned that such forward-looking statements are subject to inherent risk and that actual results may differ materially from such forward-looking statements. Further, investors are cautioned that Chemed does not assume any obligation to update forward-looking statements based on unanticipated events or changed expectations.

CONTACT: Michael D. Witzeman (513) 762-6714  

On April 21, 2026, Chemed Corp CHE shares fell 3.1% to $373.79, continuing a downward trend with a year-to-date loss of 12.5%. The stock has traded between a 52-week high of $593.81 and a low of $365.21 over the past year.

GF Value™ verdict: Chemed Corp is currently priced at $373.79, which is 42.8% undervalued compared to its GF Value™ of $653.26.GF Score™: With a score of 77/100, Chemed Corp is ranked as above average in terms of its overall financial health.Most notable signal: Financial strength is rated 9/10, indicating a robust position for the company. Is CHE Overvalued or Undervalued? Chemed Corp's current market price of $373.79 represents a significant discount relative to its GF Value™ of $653.26, suggesting the stock is undervalued by approximately 42.8%. This substantial margin of safety could present an attractive opportunity for potential investors. The GF Valuation label of "Significantly Undervalued" further emphasizes this perspective, indicating that the stock may be undervalued based on various intrinsic value calculations.

However, while the undervaluation presents a potential opportunity, caution is warranted. The stock has experienced a notable decline of 33.4% over the past year, which may reflect underlying issues or market sentiments that could impact future performance. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.

How Does CHE's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 20.4x 28.1x Forward P/E 15.6x N/A The current P/E (TTM) of 20.4x is 28% below its 5-year median P/E of 28.1x, indicating that Chemed Corp is trading at a lower valuation compared to its historical average. This analysis is consistent with the GF Value™ verdict that suggests the stock is undervalued, reinforcing the opportunity for potential investors.

What Does CHE's GF Score™ Tell Us? Metric Rating GF Score™ 77 Financial Strength 9/10 Profitability 8/10 Growth 8/10 Valuation 4/10 Momentum 1/10 Chemed Corp's GF Score™ of 77 indicates solid overall performance, particularly in Financial Strength (9/10), Profitability (8/10), and Growth (8/10). These strengths suggest that the company has a robust financial position and a solid growth trajectory. However, the lower Valuation (4/10) and extremely low Momentum (1/10) signal that the stock may have experienced recent challenges, contributing to its current undervaluation according to GF Value™.

What Are Insiders Doing with CHE Stock? In the last three months, insiders at Chemed Corp have sold $1.4 million in shares without any reported purchases. This pattern of selling could indicate a lack of confidence in the stock's short-term performance, which may concern potential investors. Insider activity is often viewed as a barometer of management's outlook on the company's future, and the absence of buying might suggest that insiders do not see the stock as a good investment at its current price.

What This Means for Investors Based on the analysis of GF Value™, Chemed Corp is currently undervalued, presenting a potential opportunity for investors looking for stocks with strong financial health and growth potential. However, potential investors should exercise caution due to recent insider selling and the stock's declining momentum.

For the complete analysis, visit the Chemed Corp CHE stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is CHE's GF Score™?

Chemed Corp has a GF Score™ of 77/100, indicating above-average performance across various financial metrics.

Is CHE overvalued or undervalued?

Chemed Corp is currently undervalued, with a GF Value™ of $653.26 compared to its market price of $373.79, suggesting significant upside potential.

What is CHE's P/E ratio?

The current P/E (TTM) for Chemed Corp is 20.4x, which is 28% below its 5-year median P/E of 28.1x, indicating that the stock is trading at a lower valuation historically.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Full-Year Guidance Increased Due To:

Strong VITAS PerformanceRe-purchase of 500,000 Shares in the QuarterTwo Roto-Rooter Franchises Purchased for $20.6 Million CINCINNATI, April 23, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its first quarter ended March 31, 2026, versus the comparable prior-year period.

Results for Quarter Ended March 31, 2026

Consolidated operating results:

Revenue increased 1.6% to $657.5 millionGAAP Diluted Earnings-per-Share (EPS) of $4.84, a decrease of 0.4%Adjusted Diluted EPS of $5.65, an increase of 0.4% VITAS segment operating results:

Net Patient Revenue of $420.0 million, an increase of 3.1%Average Daily Census (ADC) of 22,723, an increase of 2.2%Admissions of 19,394, an increase of 6.9%Net Income, excluding certain discrete items, of $52.2 million, an increase of 4.4%Adjusted EBITDA, excluding Medicare Cap, of $70.8 million, an increase of 0.6%Adjusted EBITDA margin, excluding Medicare Cap, of 16.8%, a decrease of 41-basis points Roto-Rooter segment operating results:

Revenue of $237.5 million, a decrease of 0.9%Net Income, excluding certain discrete items, of $37.7 million, a decrease of 9.7%Adjusted EBITDA of $53.5 million, a decline of 9.6%Adjusted EBITDA margin of 22.5%, a decline of 218-basis points VITAS

VITAS net revenue was $420.0 million in the first quarter of 2026, which is an increase of 3.1% when compared to the prior-year period. This revenue increase is comprised primarily of a 2.2% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.6%. Acuity mix shift negatively impacted revenue growth 120-basis points in the quarter when compared to the prior-year period’s revenue and level-of-care mix. The combination of Medicare Cap and other contra revenue changes negatively impacted revenue growth by 47-basis points.

Total VITAS admissions increased 6.9% in the first quarter of 2026 compared to the first quarter of 2025.

In the first quarter of 2026, VITAS accrued $2.4 million in Medicare Cap billing limitation. No Medicare Cap billing limitation was recorded in the first quarter of 2026 for the Florida combined program and none is anticipated for the 2026 fiscal period.

Of VITAS’ 33 Medicare provider numbers, 25 provider numbers have an anticipated full-year Medicare Cap cushion of 10% or greater, four provider numbers have a cushion between 0% and 10%, and four provider numbers have a Medicare Cap billing limitation totaling $9.5 million.

Average revenue per patient per day in the first quarter of 2026 was $210.62 which is 146-basis points above the prior-year period. Reimbursement for routine home care and high-acuity care averaged $188.59 and $1,131.82, respectively. During the quarter, high-acuity days-of-care were 2.3% of total days of care, a decline of 28-basis points when compared to the prior-year quarter.

The first quarter 2026 gross margin, excluding Medicare Cap, was 22.9%, a 71-basis point decline from the same period of 2025. Selling, general and administrative expenses were $26.1 million in the first quarter of 2026 compared to $26.5 million in the prior-year quarter.

Adjusted EBITDA, excluding Medicare Cap, totaled $70.8 million in the quarter, an increase of 0.6% when compared to the prior-year period. Adjusted EBITDA margin in the quarter, excluding Medicare Cap, was 16.8%.

Roto-Rooter

Roto-Rooter generated quarterly revenue of $237.5 million in the first quarter of 2026, a decrease of 0.9%, when compared to the prior-year quarter.

Roto-Rooter branch commercial revenue in the quarter totaled $56.5 million, a decrease of 1.9% from the prior-year period. This aggregate commercial revenue change consisted of excavation declining 7.8%, water restoration declining 10.0% and drain cleaning declining 0.9%, offset by an increase in plumbing of 3.9%.

Roto-Rooter branch residential revenue in the quarter totaled $166.3 million, a decrease of 1.5%, over the prior-year period. This aggregate residential revenue change consisted of water restoration declining 11.8% offset by plumbing increasing 9.3%, excavation increasing 0.9%, and drain cleaning increasing of 1.1%.

In the first quarter of 2026, revenue from independent contractors was $17.8 million which is a decline of 3.3% as compared to the same period of 2025.

Roto-Rooter’s first quarter 2026 gross margin was 51.0%. This compares to the prior-year quarter’s gross margin of 50.9%. Roto-Rooter’s selling, general and administrative expenses were $67.9 million in the quarter, which is an increase of 8.4% compared to the first quarter of 2025.

Adjusted EBITDA in the first quarter of 2026 totaled $53.5 million, a decrease of 9.6% when compared to the first quarter of 2025. The Adjusted EBITDA margin in the quarter was 22.5% which represents a 218-basis point decline from the first quarter of 2025.

On March 31, 2026, Roto-Rooter purchased the territory and assets of the franchises operating in San Francisco, California and Fort Worth, Texas in two separate transactions. The aggregated, combined purchase price of these transactions was approximately $20.6 million. Collectively, these Roto-Rooter locations serve a population of approximately 3.3 million people. This purchase is part of Roto-Rooter’s ongoing strategy of acquiring franchises to boost productivity, market share and profitability. These two acquisitions are anticipated to add $5.0 million to $5.5 million of revenue for the remainder of 2026.

Chemed Consolidated

As of March 31, 2026, Chemed had total cash and cash equivalents of $16.9 million and $91.2 million in long-term debt.

In April 2026, Chemed entered into a new five-year $450 million Amended and Restated Credit Agreement (Credit Agreement). This Credit Agreement consists of a $450 million revolving line of credit and a $250 million expansion feature. The interest rate on this Credit Agreement has a floating rate that is currently SOFR plus 100-basis points. There is approximately $313.3 million undrawn borrowing capacity under the Credit Agreement after excluding $45.5 million for Letters of Credit.

During the quarter, the Company repurchased 500,000 shares of Chemed stock for $197.7 million which equates to a cost per share of $395.36. As of March 31, 2026, there was approximately $229.6 million of remaining share repurchase authorization under its plan.

Guidance Update

Historically, we do not give quarterly updates to guidance. Due to the materially improved performance of VITAS, coupled with the level of share repurchases in the first quarter of 2026, we believe updating guidance is appropriate in this instance. Further operational detail will be provided during the investor conference call.

VITAS’ initiatives to return to a normal growth pattern after managing the 2025 Medicare Cap issue were more quickly successful than originally anticipated. This led to higher revenue, excluding the impact of Medicare Cap, and adjusted EBITDA margins, excluding the impact of Medicare Cap, in the first quarter 2026 than what was included in the original guidance. As a result, anticipated ADC growth for 2026 is updated to a revised range of 4.5% to 5.5% compared to the original guidance range of 3.5% to 4.0%. Anticipated revenue growth, excluding the impact of the Medicare Cap, improves from the original guidance range of 5.5% to 6.5% to a revised range of 6.5% to 7.5%. Finally, revised EBITDA margin, excluding the impact of the Medicare Cap, is anticipated to be 18.0% to 18.5% compared to the original guidance of 17.5% to 18.5%.

Roto-Rooter performed generally within our expectations. In total, there were various headwinds and tailwinds that contributed to the overall results in the first quarter of 2026.

In the first quarter of 2026, unusual ice and snowstorms led to some level of service disruption for five days of the quarter across 24 Roto-Rooter branches. This resulted in an estimated loss of net revenue of between $3 million and $4 million in the quarter.

Additionally, total leads for Roto-Rooter increased 3.3% during the quarter but continuing the previously discussed trends, a larger portion of those leads were the result of paid internet marketing. As a result, total marketing expense during the quarter exceeded our expectations by approximately $2.0 million.

When factoring all the gives and takes within the expected Roto-Rooter performance for the remainder of fiscal 2026, anticipated revenue growth remains unchanged at 3.0% to 3.5%. Estimated adjusted EBITDA margin is lowered slightly to 21.5% to 22.5% compared to the original guidance range of 22.5% to 23.0%. This is primarily due to elevated marketing costs now expected to persist above our original guidance for the remainder of the year.

Based on the above, full-year 2026 earnings per diluted share, excluding non-cash expenses for stock options, tax benefits from stock option exercises, costs related to litigation and other discrete items, is estimated to be in the range of $24.00 to $24.75. The mid-point of the revised guidance represents a 13% increase from 2025 adjusted earnings per diluted share of $21.55. The revised 2026 guidance assumes an effective corporate tax rate on adjusted earnings of 24.5% and a diluted share count of 13.6 million shares. The original 2026 guidance was for adjusted earnings per diluted share to be between $23.25 and $24.25.

Conference Call

As previously disclosed, Chemed will host a conference call and webcast at 10 a.m., ET, on Friday April 24, 2026, to discuss the company's quarterly results and to provide an update on its business. Participants may access a live webcast of the conference call through the investor relations section of Chemed’s website, Investor Relations Home | Chemed Corporation or the hosting website https://edge.media-server.com/mmc/p/o65jro38.

Participants may also register via teleconference at:
https://register-conf.media-server.com/register/BI6f413b6cd3ee468481cac75d7519454e.

Once registration is completed, participants will be provided with a dial-in number containing a personalized conference code to access the call. All participants are instructed to dial-in 15 minutes prior to the start time.

A taped replay of the conference call will be available beginning approximately two hours after the call's conclusion. You may access the replay via webcast through the investor relations section of Chemed’s website.

Chemed operates in the healthcare field through its VITAS Healthcare Corporation subsidiary. VITAS provides daily hospice services to patients with severe, life-limiting illnesses. This type of care is focused on making the terminally ill patient's final days as comfortable and pain-free as possible.

Chemed operates in the residential and commercial plumbing and drain cleaning industry under the brand name Roto-Rooter. Roto-Rooter provides plumbing, drain cleaning, and water cleanup services through company-owned branches, independent contractors and franchisees in the United States and Canada. Roto-Rooter also has licensed master franchisees in the republics of Indonesia and Singapore, and the Philippines.

This press release contains information about Chemed’s EBITDA, Adjusted EBITDA, and Adjusted Diluted EPS, which are not measures derived in accordance with GAAP and which exclude components that are important to understanding Chemed’s financial performance. In reporting its operating results, Chemed provides EBITDA, Adjusted EBITDA and Adjusted Diluted EPS measures to help investors and others evaluate the Company’s operating results, compare its operating performance with that of similar companies that have different capital structures and evaluate its ability to meet its future debt service, capital expenditures and working capital requirements. Chemed’s management similarly uses EBITDA, Adjusted EBITDA, and Adjusted Diluted EPS to assist it in evaluating the performance of the Company across fiscal periods and in assessing how its performance compares to its peer companies. These measures also help Chemed’s management to estimate the resources required to meet Chemed’s future financial obligations and expenditures. Chemed’s EBITDA, Adjusted EBITDA and Adjusted Diluted EPS should not be considered in isolation or as a substitute for comparable measures calculated and presented in accordance with GAAP. We calculated Adjusted EBITDA Margin by dividing Adjusted EBITDA by service revenue and sales. A reconciliation of Chemed’s net income to its EBITDA, Adjusted EBITDA and Adjusted Diluted EPS is presented in the tables following the text of this press release.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 REGARDING FORWARD-LOOKING INFORMATION

Statements in this press release contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods and are based upon assumptions subject to certain known and unknown risks, uncertainties, contingencies and other factors, including, but not limited to, the impact of laws and regulations on Chemed’s operations, including Medicare Cap and Medicare reimbursement rates, Chemed’s estimates of the effect of Medicare Cap on VITAS’ revenues and future prospects, Chemed’s expectations regarding VITAS’ patient mix and Chemed’s expectations regarding demand for Roto-Rooter’s services.

Because forward looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Chemed’s control. Chemed’s actual results and financial condition may differ materially from those indicated in the forward-looking statements included in this press release, including as a result of the risks described above and those described in the Chemed’s Annual Report on Form 10-K for the year ended December 31, 2025 and in its Quarterly Reports filed in 2026. Any forward-looking statement made by Chemed in this press release is based only on information currently available to Chemed and speaks only as of the date on which it is made. Chemed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

CHEMED CORPORATION AND SUBSIDIARY COMPANIESCONSOLIDATED STATEMENTS OF INCOME(in thousands, except per share data) (unaudited)         Three Months Ended March 31,  2026
 2025
Service revenues and sales $657,513  $646,943 Cost of services provided and goods sold  441,749   430,530 Selling, general and administrative expenses (aa)  114,321   105,587 Depreciation  14,303   13,445 Amortization  2,570   2,572 Other operating (income)/expense  (8)  51 Total costs and expenses  572,935   552,185 Income from operations  84,578   94,758 Interest expense  (512)  (329)Other income--net (bb)  4,774   1,245 Income before income taxes  88,840   95,674 Income taxes  (22,538)  (23,917)Net income $66,302  $71,757 Earnings Per Share      Net income $4.85  $4.91 Average number of shares outstanding  13,675   14,622 Diluted Earnings Per Share      Net income $4.84  $4.86 Average number of shares outstanding  13,690   14,764        (aa)    Selling, general and administrative ("SG&A") expenses comprise (in thousands):         Three Months Ended March 31,  2026
 2025
SG&A expenses before long-term incentive compensation      and the impact of market value adjustments related to      deferred compensation plans $108,931  $103,760 Market value adjustments related to deferred       compensation trusts  3,885   (830)Long-term incentive compensation  1,505   2,657 Total SG&A expenses $114,321  $105,587        (bb)    Other income--net comprises (in thousands):  Three Months Ended March 31,  2026
 2025
       Market value adjustments related to deferred      compensation trusts $3,885  $(830)Interest income  890   2,076 Other  (1)  (1)Total other income--net $4,774  $1,245         CHEMED CORPORATION AND SUBSIDIARY COMPANIESCONSOLIDATED BALANCE SHEETS(in thousands, except per share data) (unaudited)         March 31,  2026
 2025
Assets      Current assets      Cash and cash equivalents $16,856  $173,882 Accounts receivable less allowances  215,479   285,873 Inventories  7,208   7,790 Prepaid income taxes  7,614   4,436 Prepaid expenses  26,906   30,404 Total current assets  274,063   502,385 Investments of deferred compensation plans held in trust  143,778   127,949 Properties and equipment, at cost less accumulated depreciation  207,734   199,679 Lease right of use asset  133,597   131,150 Identifiable intangible assets less accumulated amortization  80,417   89,929 Goodwill  687,501   666,940 Other assets  8,725   8,483 Total Assets $1,535,815  $1,726,515 Liabilities      Current liabilities      Accounts payable $65,698  $47,692 Accrued insurance  65,101   65,743 Accrued income taxes  25,770   38,247 Accrued compensation  62,750   59,905 Short-term lease liability  41,286   42,976 Other current liabilities  60,810   35,993 Total current liabilities  321,415   290,556 Deferred income taxes  14,575   11,771 Deferred compensation liabilities  142,660   127,292 Long-term debt  91,200   - Long-term lease liability  104,448   102,082 Other liabilities  13,523   13,052 Total Liabilities  687,821   544,753 Stockholders' Equity      Capital stock  37,607   37,535 Paid-in capital  1,603,730   1,538,419 Retained earnings  3,013,504   2,786,264 Treasury stock, at cost  (3,809,245)  (3,182,718)Deferred compensation payable in Company stock  2,398   2,262 Total Stockholders' Equity  847,994   1,181,762 Total Liabilities and Stockholders' Equity $1,535,815  $1,726,515         CHEMED CORPORATION AND SUBSIDIARY COMPANIES CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) (unaudited)           For the Three Months Ended March 31,   2026
 2025
 Cash Flows from Operating Activities       Net income $66,302  $71,757  Adjustments to reconcile net income to net cash provided       by operating activities:       Depreciation and amortization  16,873   16,017  Stock option expense  9,249   9,091  Benefit for deferred income taxes  (4,737)  (14,174) Noncash long-term incentive compensation  1,386   2,420  Amortization of debt issuance costs  80   80  Changes in operating assets and liabilities, excluding       amounts acquired in business combinations:       Increase in accounts receivable  (32,899)  (67,424) Decrease in inventories  335   403  Increase in prepaid expenses  (88)  (4,430) Increase/(decrease) in accounts payable and       other current liabilities  2,235   (22,592) Change in current income taxes  26,817   37,286  Net change in lease assets and liabilities  (471)  169  (Increase)/decrease in other assets  (3,603)  3,034  Increase in other liabilities  6,709   951  Other sources  31   156  Net cash provided by operating activities  88,219   32,744  Cash Flows from Investing Activities       Business combinations, net of cash acquired  (20,610)  (225) Capital expenditures  (17,116)  (13,280) Proceeds from sale of fixed assets  134   112  Other uses  (197)  (281) Net cash used by investing activities  (37,789)  (13,674) Cash Flows from Financing Activities       Purchases of treasury stock  (190,039)  (33,222) Proceeds from revolving line of credit  135,480   -  Payments on revolving line of credit  (44,280)  -  Dividends paid  (8,173)  (7,325) Capital stock surrendered to pay taxes on stock-based compensation  (1,482)  (6,254) Proceeds from exercise of stock options  1,312   22,666  Change in cash overdrafts payable  (493)  438  Other (uses)/sources  (414)  159  Net cash used by financing activities  (108,089)  (23,538) Decrease in Cash and Cash Equivalents  (57,659)  (4,468) Cash and cash equivalents at beginning of year  74,515   178,350  Cash and cash equivalents at end of period $16,856  $173,882           CHEMED CORPORATION AND SUBSIDIARY COMPANIES CONSOLIDATING STATEMENTS OF INCOME FOR THE THREE MONTHS ENDED MARCH 31, 2026 AND 2025 (in thousands) (unaudited)         Chemed   VITAS Roto-Rooter Corporate Consolidated 2026 (a)             Service revenues and sales $420,018  $237,495  $-  $657,513  Cost of services provided and goods sold  325,467   116,282   -   441,749  Selling, general and administrative expenses  26,109   67,929   20,283   114,321  Depreciation  5,912   8,379   12   14,303  Amortization  26   2,544   -   2,570  Other operating expense/(income)  52   (60)  -   (8) Total costs and expenses  357,566   195,074   20,295   572,935  Income/(loss) from operations  62,452   42,421   (20,295)  84,578  Interest expense  (50)  (136)  (326)  (512) Intercompany interest income/(expense)  6,238   4,512   (10,750)  -  Other income—net  95   15   4,664   4,774  Income/(loss) before income taxes  68,735   46,812   (26,707)  88,840  Income taxes  (16,528)  (11,028)  5,018   (22,538) Net income/(loss) $52,207  $35,784  $(21,689) $66,302                2025 (b)             Service revenues and sales $407,400  $239,543  $-  $646,943  Cost of services provided and goods sold  312,807   117,723   -   430,530  Selling, general and administrative expenses  26,538   62,649   16,400   105,587  Depreciation  5,196   8,237   12   13,445  Amortization  26   2,546   -   2,572  Other operating expense/(income)  64   (13)  -   51  Total costs and expenses  344,631   191,142   16,412   552,185  Income/(loss) from operations  62,769   48,401   (16,412)  94,758  Interest expense  (48)  (132)  (149)  (329) Intercompany interest income/(expense)  5,296   3,930   (9,226)  -  Other income—net  48   10   1,187   1,245  Income/(loss) before income taxes  68,065   52,209   (24,600)  95,674  Income taxes  (18,035)  (12,265)  6,383   (23,917) Net income/(loss) $50,030  $39,944  $(18,217) $71,757                              The "Footnotes to Financial Statements" are integral parts of this financial information.                              CHEMED CORPORATION AND SUBSIDIARY COMPANIES CONSOLIDATING SUMMARIES OF EBITDA FOR THREE MONTHS ENDED MARCH 31, 2026 AND 2025 (in thousands) (unaudited)         Chemed   VITAS Roto-Rooter Corporate Consolidated 2026             Net income/(loss) $52,207  $35,784  $(21,689) $66,302  Add/(deduct):             Interest expense  50   136   326   512  Income taxes  16,528   11,028   (5,018)  22,538  Depreciation  5,912   8,379   12   14,303  Amortization  26   2,544   -   2,570  EBITDA  74,723   57,871   (26,369)  106,225  Add/(deduct):             Intercompany interest expense/(income)  (6,238)  (4,512)  10,750   -  Interest income  (95)  (15)  (779)  (889) Stock option expense  -   -   9,249   9,249  Long-term incentive compensation  -   -   1,505   1,505  Acquisition expense  -   167   -   167  Adjusted EBITDA $68,390  $53,511  $(5,644) $116,257                2025             Net income/(loss) $50,030  $39,944  $(18,217) $71,757  Add/(deduct):             Interest expense  48   132   149   329  Income taxes  18,035   12,265   (6,383)  23,917  Depreciation  5,196   8,237   12   13,445  Amortization  26   2,546   -   2,572  EBITDA  73,335   63,124   (24,439)  112,020  Add/(deduct):             Intercompany interest expense/(income)  (5,296)  (3,930)  9,226   -  Interest income  (49)  (10)  (2,017)  (2,076) Stock option expense  -   -   9,091   9,091  Long-term incentive compensation  -   -   2,657   2,657  Adjusted EBITDA $67,990  $59,184  $(5,482) $121,692                The "Footnotes to Financial Statements" are integral parts of this financial information.                CHEMED CORPORATION AND SUBSIDIARY COMPANIESRECONCILIATION OF ADJUSTED NET INCOME(in thousands, except per share data)(unaudited)              Three Months Ended March 31,   2026
 2025
 Net income as reported $66,302  $71,757  Add/(deduct) pre-tax cost of:       Stock option expense  9,249   9,091  Amortization of reacquired franchise rights  2,352   2,352  Long-term incentive compensation  1,505   2,657  Acquisition expense  167   -  Add/(deduct) tax impacts:       Tax impact of the above pre-tax adjustments (1)  (2,248)  (2,320) Excess tax expenses/(benefits) on stock compensation  56   (463) Adjusted net income $77,383  $83,074          Diluted Earnings Per Share As Reported       Net income $4.84  $4.86  Average number of shares outstanding  13,690   14,764          Adjusted Diluted Earnings Per Share       Adjusted net income $5.65  $5.63  Average number of shares outstanding  13,690   14,764          (1) The tax impact of pre-tax adjustments was calculated using the effective tax rate of the operating unit for which each adjustment is associated.        The "Footnotes to Financial Statements" are integral parts of this financial information.         CHEMED CORPORATION AND SUBSIDIARY COMPANIESOPERATING STATISTICS FOR VITAS SEGMENT(unaudited) Three Months Ended March 31,OPERATING STATISTICS2026
 2025
Net revenue ($000) (c)     Homecare$371,091  $351,566 Inpatient 35,925   34,022 Continuous care 18,133   24,637 Other 5,578   5,344 Subtotal$430,727  $415,569 Room and board, net (3,257)  (3,525)Contractual allowances (5,077)  (2,319)Medicare cap allowance (2,375)  (2,325)Net Revenue$420,018  $407,400 Net revenue as a percent of total before Medicare cap allowance     Homecare 86.2%  84.6%Inpatient 8.3   8.2 Continuous care 4.2   5.9 Other 1.3   1.3 Subtotal 100.0   100.0 Room and board, net (0.8)  (0.8)Contractual allowances (1.1)  (0.6)Medicare cap allowance (0.6)  (0.6)Net Revenue 97.5%  98.0%Days of care     Homecare 1,691,619   1,632,569 Nursing home 294,818   307,108 Respite 10,875   9,995 Subtotal routine homecare and respite 1,997,312   1,949,672 Inpatient 30,474   29,704 Continuous care 17,288   22,620 Total 2,045,074   2,001,996       Number of days in relevant time period 90   90 Average daily census ("ADC") (days)     Homecare 18,796   18,140 Nursing home 3,276   3,412 Respite 120   111 Subtotal routine homecare and respite 22,192   21,663 Inpatient 339   330 Continuous care 192   251 Total 22,723   22,244       Total Admissions 19,394   18,139 Total Discharges 18,537   17,875 Average length of stay (days) 102.7   118.7 Median length of stay (days) 15.0   16.0       ADC by major diagnosis     Cerebro 44.5%  44.7%Neurological 11.3   12.4 Cancer 9.6   9.6 Cardio 16.3   16.1 Respiratory 7.7   7.2 Other 10.6   10.0 Total 100.0%  100.0%Admissions by major diagnosis     Cerebro 26.9%  28.4%Neurological 6.9   6.5 Cancer 23.5   24.6 Cardio 15.8   15.0 Respiratory 12.4   11.6 Other 14.5   13.9 Total 100.0%  100.0%      Estimated uncollectible accounts as a percent of revenues 1.2%  0.6%      Accounts receivable --     Days of revenue outstanding-excluding unapplied Medicare payments38.8   47.3 Days of revenue outstanding-including unapplied Medicare payments33.6   44.5        CHEMED CORPORATION AND SUBSIDIARY COMPANIES FOOTNOTES TO FINANCIAL STATEMENTS FOR THE THREE MONTHS AND YEARS ENDED MARCH 31, 2026 AND 2025 (unaudited)                (a)Included in the results of operations for 2026 are the following significant credits/(charges) which may not be indicative of ongoing operations  (in thousands):                Three Months Ended March 31, 2026    VITAS Roto-Rooter Corporate Consolidated                 Stock option expense $- $-  $(9,249) $(9,249)  Amortization of reacquired franchise agreements  -  (2,352)  -   (2,352)  Long-term incentive compensation  -  -   (1,505)  (1,505)  Acquisition expense  -  (167)  -   (167)  Pretax impact on earnings  -  (2,519)  (10,754)  (13,273)  Excess tax expenses on stock compensation  -  -   (56)  (56)  Income tax benefit on the above  -  587   1,661   2,248   After-tax impact on earnings $- $(1,932) $(9,149) $(11,081)                (b)Included in the results of operations for 2025 are the following significant credits/(charges) which may not be indicative of ongoing operations  (in thousands):                Three Months Ended March 31, 2025    VITAS Roto-Rooter Corporate Consolidated                 Stock option expense $- $-  $(9,091) $(9,091)  Long-term incentive compensation  -  -   (2,657)  (2,657)  Amortization of reacquired franchise agreements  -  (2,352)  -   (2,352)  Pretax impact on earnings  -  (2,352)  (11,748)  (14,100)  Excess tax benefits on stock compensation  -  -   463   463   Income tax benefit on the above  -  546   1,774   2,320   After-tax impact on earnings $- $(1,806) $(9,511) $(11,317)                               (c)VITAS has 13 large (greater than 450 ADC), 23 medium (greater than 200 but less than 450 ADC) and 23 small (less than 200 ADC) hospice programs. Of Vitas' 33 Medicare provider numbers, for the current cap year, 25 provider numbers have a Medicare cap cushion of greater than 10%, four provider numbers have a Medicare cap cushion between 0% and 10%, and four provider numbers have a Medicare cap liability.     CONTACT: 
Michael D. Witzeman                                       
(513) 762-6714

Chemed Corporation (CHE) Q1 2026 Earnings Call Transcript

Posted by Defense World Staff on Apr 26th, 2026

Cwm LLC boosted its holdings in shares of Chemed Corporation (NYSE:CHE – Free Report) by 88.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,084 shares of the company’s stock after purchasing an additional 1,914 shares during the period. Cwm LLC’s holdings in Chemed were worth $1,747,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CHE. Geneos Wealth Management Inc. lifted its position in Chemed by 330.4% during the first quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock valued at $61,000 after purchasing an additional 76 shares during the period. Arrowstreet Capital Limited Partnership lifted its position in Chemed by 67.0% during the second quarter. Arrowstreet Capital Limited Partnership now owns 11,365 shares of the company’s stock valued at $5,534,000 after purchasing an additional 4,560 shares during the period. Marshall Wace LLP acquired a new position in Chemed during the second quarter valued at $579,000. Brown Advisory Inc. lifted its position in Chemed by 36.9% during the second quarter. Brown Advisory Inc. now owns 549 shares of the company’s stock valued at $267,000 after purchasing an additional 148 shares during the period. Finally, Cerity Partners LLC lifted its position in Chemed by 237.7% during the second quarter. Cerity Partners LLC now owns 4,451 shares of the company’s stock valued at $2,165,000 after purchasing an additional 3,133 shares during the period. 95.85% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In A number of research analysts recently issued reports on the stock. Royal Bank Of Canada restated a “sector perform” rating and set a $422.00 target price (down from $572.00) on shares of Chemed in a research report on Friday, February 27th. Zacks Research downgraded shares of Chemed from a “hold” rating to a “strong sell” rating in a research report on Wednesday, March 4th. Jefferies Financial Group downgraded shares of Chemed from a “buy” rating to a “hold” rating in a research report on Thursday, January 22nd. Oppenheimer decreased their target price on shares of Chemed from $580.00 to $500.00 and set an “outperform” rating for the company in a research report on Friday, February 27th. Finally, Weiss Ratings downgraded shares of Chemed from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, April 13th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Chemed has an average rating of “Hold” and an average target price of $498.00.

Get Our Latest Analysis on CHE

Key Chemed News Here are the key news stories impacting Chemed this week:

Positive Sentiment: Company raised FY2026 EPS guidance to $24.00–$24.75, above prior consensus, giving investors a better earnings outlook for the year. Chemed Reports First-Quarter 2026 Results Positive Sentiment: Adjusted Q1 EPS of $5.65 beat Street estimates (around $5.30), signaling core profitability resilience and helping lift sentiment. Chemed (CHE) Beats Q1 Earnings and Revenue Estimates Positive Sentiment: VITAS (hospice) showed revenue and operating improvements (net patient revenue +3.1%, higher average daily census and admissions), which management cited when raising guidance. Chemed Reports First-Quarter 2026 Results Neutral Sentiment: Revenue was roughly flat/only modestly up (+1.6% to $657.5M), essentially in line with expectations — not a growth surprise but not a miss either. Press Release / Slide Deck Neutral Sentiment: Cash from operations improved meaningfully and the company repurchased 500,000 shares and closed two Roto‑Rooter franchise purchases (~$20.6M) — capital allocation activity that investors may view positively over time. Chemed Reports First-Quarter 2026 Results Negative Sentiment: Roto‑Rooter showed revenue and EBITDA declines and margin compression (notable drop in segment EBITDA and margins), a near‑term drag on consolidated profitability. Chemed earnings on deck as hospice, plumbing units face tests Negative Sentiment: GAAP diluted EPS and net income were slightly down year‑over‑year, and balance‑sheet notes (lower cash, higher liabilities) plus recent insider sales may concern some investors focused on capital structure. Chemed Corp (CHE) Stock Rises on Q1 2026 Earnings Chemed Stock Performance Shares of Chemed stock opened at $420.67 on Friday. The firm has a 50-day simple moving average of $403.17 and a two-hundred day simple moving average of $426.24. The company has a market cap of $6.15 billion, a P/E ratio of 22.92, a price-to-earnings-growth ratio of 1.52 and a beta of 0.49. Chemed Corporation has a fifty-two week low of $365.20 and a fifty-two week high of $583.96.

Chemed (NYSE:CHE – Get Free Report) last issued its quarterly earnings data on Thursday, April 23rd. The company reported $5.65 earnings per share for the quarter, topping analysts’ consensus estimates of $5.30 by $0.35. The business had revenue of $657.51 million during the quarter, compared to the consensus estimate of $659.22 million. Chemed had a net margin of 10.23% and a return on equity of 25.70%. The company’s revenue was up 1.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $5.63 earnings per share. Chemed has set its FY 2026 guidance at 24.000-24.75 EPS. Equities research analysts forecast that Chemed Corporation will post 21.92 EPS for the current year.

Chemed Dividend Announcement The company also recently disclosed a quarterly dividend, which was paid on Friday, March 13th. Shareholders of record on Monday, February 23rd were given a $0.60 dividend. The ex-dividend date was Monday, February 23rd. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.6%. Chemed’s dividend payout ratio is 13.08%.

Insider Buying and Selling at Chemed In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the company’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $403.18, for a total value of $806,360.00. Following the completion of the transaction, the chief executive officer owned 93,719 shares in the company, valued at approximately $37,785,626.42. This represents a 2.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 3.29% of the company’s stock.

Chemed Company Profile (Free Report)

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.

Further Reading Five stocks we like better than Chemed

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINETechnipFMC plc $FTI Shares Acquired by Farther Finance Advisors LLC

NEXT HEADLINE »Bartlett & CO. Wealth Management LLC Has $212.21 Million Stock Position in Amazon.com, Inc. $AMZN

CINCINNATI, May 05, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the Bank of America Securities 2026 Health Care Conference on Tuesday, May 12, 2026, at 3:00 PM (PDT) at the Encore at the Wynn Las Vegas.

The presentation will be webcast live and can be accessed, along with the presentation materials, through the Chemed website at www.chemed.com (Investor Relations). The webcast replay will be available within 24 hours of the live presentation and will be accessible for 90 days.

Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation (www.chemed.com) operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation's largest provider of end-of-life hospice care and Roto-Rooter is the nation’s leading provider of plumbing and drain cleaning services.

Statements in this press release or in other Chemed communications may relate to future events or Chemed's future performance. Such statements are forward-looking statements and are based on present information Chemed has related to its existing business circumstances. Investors are cautioned that such forward-looking statements are subject to inherent risk that actual results may differ materially from such forward-looking statements. Further, investors are cautioned that Chemed does not assume any obligation to update forward-looking statements based on unanticipated events or changed expectations.

CONTACT:Michael D. Witzeman
(513) 762-6714  

Chemed Corporation (CHE) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Chemtrade Logistics Income Fund (CHE.UN:CA) Q1 2026 Earnings Call Prepared Remarks Transcript

Chemed Corporation (CHE) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

CINCINNATI, June 08, 2026 (GLOBE NEWSWIRE) -- Roto-Rooter Services Company, a wholly owned subsidiary of Chemed Corporation ("Chemed") (NYSE: CHE) announced it has acquired a formerly independent Roto-Rooter franchise serving 21 counties in south Texas for approximately $12.0 million. The service area includes the cities of Corpus Christi, McAllen, Laredo and Brownsville, Texas.

Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation (www.chemed.com) operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation's largest provider of end-of-life hospice care and Roto-Rooter is the nation’s leading provider of plumbing and drain cleaning services.

Statements in this press release or in other Chemed communications may relate to future events or Chemed's future performance. Such statements are forward-looking statements and are based on present information Chemed has related to its existing business circumstances. Investors are cautioned that such forward-looking statements are subject to inherent risk and that actual results may differ materially from such forward-looking statements. Further, investors are cautioned that Chemed does not assume any obligation to update forward-looking statements based on unanticipated events or changed expectations.

CONTACT: 
Michael D. Witzeman
(513) 762-6714